Prothena Corporation plc is a clinical-stage biotechnology firm developing therapeutic antibodies and vaccines aimed at treating neurodegenerative and protein-misfolding diseases. The company's pipeline includes multiple candidates in various development phases, such as Prasinezumab for Parkinson's disease and synucleinopathies, Coramitug for transthyretin amyloidosis, and tau and amyloid-beta directed therapies for Alzheimer's disease, along with programs targeting TDP-43 for amyotrophic lateral sclerosis. Prothena has partnerships with Roche for alpha-synuclein-targeting antibodies and with Bristol Myers Squibb for tau and TDP-43 programs.
1Y: 8.46 (+3.4%) · range 7.91–11.51
entry readiness 65 · MODERATE · exit proximity 0
Value area 8.38–10.09 · 89% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| short-interest | 1.000 | Aug 31, 2026 |
| squeeze-risk | 0.677 | Aug 31, 2026 |
| earnings-surprise | 0.033 | Sep 4, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.11% | +8.75% | 15/20d |
| 40d | -1.11% | +8.75% | 15/40d |